2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-CauseNovel therapeuticsEconomic burdenSurvivalRational Design of TDP-43 Derived α‑Helical Peptide Inhibitors: An In Silico Strategy to Prevent TDP-43 Aggregation in Neurodegenerative Disorders
Salaikumaran M, Gopal P. Rational Design of TDP-43 Derived α‑Helical Peptide Inhibitors: An In Silico Strategy to Prevent TDP-43 Aggregation in Neurodegenerative Disorders. ACS Chemical Neuroscience 2024, 15: 1096-1109. PMID: 38466778, PMCID: PMC10959110, DOI: 10.1021/acschemneuro.3c00659.Peer-Reviewed Original ResearchConceptsMolecular dynamics simulationsTDP-43 aggregationTDP-43Disordered C-terminal regionDynamics simulationsIntramolecular hydrogen bondsAmyloid-like filamentsPeptide inhibitorRNA/DNA-binding proteinC-terminal regionPathology of neurodegenerative diseasesNeurodegenerative diseasesAggregation of TDP-43Binding affinityStructure-based computational approachDesign of peptide inhibitorsRNA/DNA-bindingLow root-mean-square deviationRNA splicingMRNA transportPeptide-based therapeuticsRoot-mean-square deviationDevelopment of novel therapeuticsFree energy landscapeStructure predictionPrescription Drug Prices: An AAN Position Statement.
Santoro J, Sico J, Burke J, Sarkar K, Turbes M, Evans D, Jordan J. Prescription Drug Prices: An AAN Position Statement. Neurology 2024, 102: e209132. PMID: 38335469, DOI: 10.1212/wnl.0000000000209132.Peer-Reviewed Original ResearchConceptsHigh cost of medicationNeurological disordersDevelopment of novel therapeuticsNeurological diseasesOrphan Drug ActTherapeutic optionsCost of medicationsHigh-value careCost of prescription drugsPrescription drug pricesRare diseaseTreat rare diseasesPatientsNovel therapeuticsTreat neurological disordersDrug ActCost containment effortsChronic neurological conditionsEffective prescription medicationsMedicationPrescriber accessPrescription medicationsTherapyHealthcare systemApproval pathway
2012
Clinical development of novel therapeutics for castration‐resistant prostate cancer
Galsky M, Small A, Tsao C, Oh W. Clinical development of novel therapeutics for castration‐resistant prostate cancer. CA A Cancer Journal For Clinicians 2012, 62: 299-308. PMID: 22535487, DOI: 10.3322/caac.21141.Peer-Reviewed Original ResearchMeSH KeywordsAndrostenesAndrostenolsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzamidesCancer VaccinesCastrationClinical Trials as TopicDenosumabDrug Therapy, CombinationHumansMaleNitrilesPhenylthiohydantoinProstate-Specific AntigenProstatic NeoplasmsPyridinesRadiopharmaceuticalsRadiumRANK LigandReceptor Protein-Tyrosine KinasesTaxoidsTissue ExtractsConceptsCastration-resistant prostate cancerProstate cancerPathogenesis of castration-resistant prostate cancerTreatment of castration-resistant prostate cancerTreatment of prostate cancerCastration-resistant diseaseUS Food and Drug AdministrationClinical development of novel therapeuticsFood and Drug AdministrationDevelopment of novel therapeuticsClinical developmentRandomized trialsClinical investigationDrug AdministrationNovel therapeuticsCancerTrial designDrugDrug developmentDiseaseTrialsTreatmentTherapyPathogenesisEndpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply